Skip to main content

Parabilis Medicines, Inc.

PBLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001657677

In the last 90 days, Parabilis Medicines, Inc. insiders filed 1 open-market purchase and 0 sales; 79 institutions reported holding it in 13F filings for Q2 2026, worth $2.71B in total; no superinvestor holds it.

Holders of 5% or more of PBLS

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Parabilis Medicines, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of PBLS
HolderLatest formStakeChangeFirst filedLatest filingFiling
Ra Capital Management, L.P.13D23.80%28.9M sharesNewJun 18, 20261 filingJun 18, 2026SEC
FMR LLC13G8.50%10.3M sharesNewAug 6, 20261 filingAug 6, 2026SEC
ARCH Venture Fund XII, L.P.13G5.30%6.41M sharesNewAug 14, 20261 filingAug 14, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

3 Schedule 13D and 13G filings on Parabilis Medicines, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on PBLS
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20264:05 PM ETARCH Venture Fund XII, L.P.and 6 others13G5.30%6.41M sharesNewJun 30, 2026SEC
Aug 6, 202610:38 AM ETFMR LLCand 1 other13G8.50%10.3M sharesNewJun 30, 2026SEC
Jun 18, 20264:09 PM ETRa Capital Management, L.P.and 3 others13D23.80%28.9M sharesNewJun 11, 2026SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Parabilis Medicines, Inc. shares.

No Form 144 notices for Parabilis Medicines, Inc. are on file.